Compare MPLX LP (MPLX) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MPLX LP vs TG Therapeutics Inc — how do they compare? MPLX LP trades at $60.05 (market cap $60.66B), while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). The key difference: MPLX LP is far larger — about 7.1× TG Therapeutics Inc's market cap, and MPLX LP pays a 7.2% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MPLX | TGTX | |
|---|---|---|
Market Cap | $60.66B | $8.53B |
Sector | Technology | Health |
52-Week High | $60.51 | $59.06 |
52-Week Low | $47.80 | $26.94 |
Enterprise Value | $85.76B | $8.74B |
Dividend Yield | 7.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MPLX trades at $59.83, up 0.27% with strong technical momentum as moving averages signal bullish conditions. The company demonstrates robust profitability with 40.45% net income margin and 33.95% ROE, though recent Q2 2026 earnings matched expectations without beating. Analyst consensus remains strongly bullish with 19 buy ratings and a $64.00 price target, representing 7% upside potential. Recent news highlights management's commitment to 12.5% annual distribution growth through 2027.
MPLX offers attractive income with 7%+ yield and distribution growth potential, supported by fee-based midstream operations. Key risks include rising leverage approaching 4x and exposure to energy market volatility. The stock presents a compelling value proposition for income-focused investors seeking energy infrastructure exposure with growth catalysts from ongoing capacity expansions.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
